Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

U.S. Food and Drug Administration Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia Collaboration with Eli Lilly and Company ...

Related Keywords

New York ,United States ,London ,City Of ,United Kingdom ,Philadelphia ,Pennsylvania ,New Zealand ,Boston ,Massachusetts ,American ,Sekar Kathiresan ,Eli Lilly ,Ashlea Kosikowski ,Frederick Fredt Fiedorek ,Jen Robinson ,Verve Therapeutics Inc ,American Heart Association ,Drug Administration ,Vertex Pharmaceuticals Incorporated ,American Heart Association Scientific Sessions ,Research Development Rd Expenses ,Company To Host Investor Event ,Exchange Commission ,Nasdaq ,Clears Investigational New Drug Application ,Heterozygous Familial Hypercholesterolemia ,Expands Through Lilly ,Product Rights ,Clinical Trial ,Scientific Sessions ,Host Investor Event ,Cash Equivalents ,Marketable Securities ,Cash Runway ,Interim Data ,Investigational New Drug Application ,Clinical Trial Initiation ,First Half ,Second Half ,Beam Therapeutics ,Jason Politi ,Healthcare Conference ,London Healthcare Conference ,Private Securities Litigation Reform Act ,Markets ,